PMID- 32991316
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 1899-1505 (Electronic)
IS  - 0867-5910 (Linking)
VI  - 71
IP  - 3
DP  - 2020 Jun
TI  - N-acetylcysteine modulates effect of the iron isomaltoside on peritoneal 
      mesothelial cells.
LID - 10.26402/jpp.2020.3.07 [doi]
AB  - Intravenous (i.v.) iron supplementation is used in patients on chronic peritoneal 
      dialysis (pd). Iron induced intraperitoneal inflammation observed in our previous 
      studies with iron sucrose may deteriorate the function of the peritoneum as the 
      dialysis membrane. We evaluated effect iron compound, iron-isomaltoside-100 (IIS) 
      on the peritoneal mesothelial cells (MC). We studied the effect of iv treatment 
      with IIS +/- N-acetylcysteine (NAC) on the dialysate parameters and function of MC. 
      In 7 uremic pd patients IIS 200 mg was infused i.v. +/- NAC 600 mg. Afterward, a 4 
      hours exchange was performed with Dianeal 1.5%. As a control dialysate exchange 
      preceding IIS treatment was used. Inflammatory parameters of the drained 
      dialysates as well as the dialysates and IIS effects on MC were evaluated in ex 
      vivo experiments. Intravenous infusion of IIS resulted in an increase of the 
      dialysate Fe (+147%, P < 0.01). Concentrations of the dialysates inflammatory 
      mediators were increased: interleukin-6 (IL-6) +39%, P < 0.02, monocyte 
      chemoattractant protein-1(MCP1) +50%, P < 0.02, and hyaluronan (HA) +64%, P < 
      0.02. Simultaneous i.v. infusion of NAC prevented increase of the dialysate 
      inflammatory mediators. Dialysates collected after IIS treatment induced 
      oxidative stress in MC (+29%, P < 0.05) and stimulated IL-6 synthesis (+64%, P < 
      0.05) in MC; no such effect was seen in dialysates obtained after simultaneous 
      IIS and NAC i.v. treatment. IIS used as the additive to culture medium stimulated 
      synthesis in MC of IL6 (+76%, P < 0.001) and plasminogen activator inhibitor-1 
      (PAI-1) (28%, P < 0.001) whereas synthesis of tissue plasminogen activator (t-PA) 
      was reduced (-16%, P < 0.001). These changes were prevented in the presence of 
      NAC 1 mmol/L. Intravenous administration of IIS results in the mild stimulation 
      of intraperitoneal inflammation. IIS changes MC phenotype to the inflammatory one 
      with reduced fibrinolytic activity. These effects are prevented by NAC.
FAU - Misian, M
AU  - Misian M
AD  - Department of Pathophysiology, Poznan University of Medical Sciences, Poznan, 
      Poland.
FAU - Baum, E
AU  - Baum E
AD  - Department of Pathophysiology, Poznan University of Medical Sciences, Poznan, 
      Poland.
FAU - Breborowicz, A
AU  - Breborowicz A
AD  - Department of Pathophysiology, Poznan University of Medical Sciences, Poznan, 
      Poland. abreb@ump.edu.pl.
LA  - eng
PT  - Journal Article
DEP - 20200926
PL  - Poland
TA  - J Physiol Pharmacol
JT  - Journal of physiology and pharmacology : an official journal of the Polish 
      Physiological Society
JID - 9114501
RN  - 0 (Cytokines)
RN  - 0 (Disaccharides)
RN  - 0 (Ferric Compounds)
RN  - 0 (Inflammation Mediators)
RN  - 3M6325NY1R (iron isomaltoside 1000)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/*administration & dosage/adverse effects
MH  - Adult
MH  - Cells, Cultured
MH  - Cytokines/metabolism
MH  - Disaccharides/*administration & dosage/adverse effects
MH  - Epithelial Cells/*drug effects/metabolism
MH  - Ferric Compounds/*administration & dosage/adverse effects
MH  - Fibrinolysis/drug effects
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/drug effects
MH  - *Peritoneal Dialysis/adverse effects
MH  - Peritoneum/*drug effects/metabolism
MH  - Phenotype
MH  - Treatment Outcome
MH  - Uremia/blood/diagnosis/*therapy
EDAT- 2020/09/30 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/05/09 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
AID - 10.26402/jpp.2020.3.07 [doi]
PST - ppublish
SO  - J Physiol Pharmacol. 2020 Jun;71(3). doi: 10.26402/jpp.2020.3.07. Epub 2020 Sep 
      26.